✳flâneur — a map of the web's best reading

Short-Bowel Syndrome Medication: GLP-2 Analogs, Growth Hormone Analogs

emedicine.medscape.com · 2,755 words · saved by 1 readers

Fluid and electrolyte management is a mainstay of therapy. Parenteral nutrition is an important therapy in the care of the patient with short-bowel syndrome. Parenteral nutrition provides adequate protein, calories, other macronutrients, and micronutrients until the bowel has had time to adapt. Pharmacologic therapies include somatropin and the glucagonlike peptide-2 (GLP-2) analogue teduglutide. Analog of naturally occurring glucagonlike peptide-2 (GLP-2) bind to the GLP-2 receptors located in intestinal subpopulations of enteroendocrine cells, subepithelial myofibroblasts, and enteric neurons of the submucosal and myenteric plexus. Binds to GLP-2 receptors and activated local release of intestinal mediators that increase intestinal absorptive capacity, resulting in increased fluid and nutrient absorption. It is indicated for adults and children aged 1 year or older with short-bowel syndrome who are dependent on parenteral support. Elicits anabolic and anticatabolic influence on vario

Short-Bowel Syndrome Medication: GLP-2 Analogs, Growth Hormone Analogs [{domaincategory=emedicine, pagename=emedicine, sspid=null, sspname=null, sspurl=null, locale=en_us, ddname=null, ddshow=0, ddorder=null, headeroverride=null, footeroverride=null}] --> close Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out Cancel processing.... Tools & Reference > General Surgery Short-Bowel Syndrome Medication Updated: Aug 27, 2024 Author: Burt Cagir, MD, FACS; Chief Editor: John Geibel, MD,

Explore this link on the map →

related reading